A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition
批准号:
10532764
负责人:
Da Yang
金额:
$36.87万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-12-01 至 2025-11-30
关键词:
AffectBioinformaticsBiological AssayBiological ProcessBreast Cancer CellCancer Cell Growth RegulationCancer PatientCancer cell lineCell physiologyChIP-seqChemoresistanceChemotherapy-Oncologic ProcedureClinicalClinical ManagementCodeComputer AnalysisDataDatabasesDevelopmentDimensionsDoxorubicinDrug EffluxDrug InteractionsDrug RegulationsDrug ScreeningEnzymesEvolutionExcretory functionGenesGenetic TranscriptionGenomicsGenotypeGoalsImmunoprecipitationIn VitroLengthLocationLuciferasesMachine LearningMalignant NeoplasmsMediatingMedicalMetabolismModelingMolecular CloningNuclear ReceptorsNucleotidesOutcomePharmaceutical PreparationsPharmacogenomicsPrimary NeoplasmProteinsRNARNA-Protein InteractionRegulationReporter GenesResearchResistanceResistance developmentSamplingSpecificityTechnologyTestingTissuesTranscriptional RegulationTreatment EfficacyUntranslated RNAUp-RegulationValidationXenobioticsabsorptioncancer cellcancer therapycancer typechemotherapyclinical prognosisconstitutive androstane receptorcrosslinking and immunoprecipitation sequencingdocetaxeldrug dispositiondrug metabolismgain of functionin vivoknock-downmachine learning modelnovelnovel strategiesoverexpressionpharmacokinetics and pharmacodynamicspregnane X receptorreceptorresponsetranscriptome sequencingtreatment responsetumoruptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and
disposition
Abstract
Drug metabolism and disposition are essential xenobiotic responses. The long non-coding RNAs (lncRNAs)
are non-coding RNAs larger than 200 nucleotides (nt) in length and do not have protein-coding potentials.
Although many of the biological functions of lncRNAs have been recognized, it is unclear whether and how
lncRNAs can regulate the expression of drug-metabolizing enzymes and transporters and if so, whether the
regulations are implicated in cancer chemo-resistance. Through integrative analysis of cancer non-coding
genomic and high-through drug screening data of 505 cancer cell lines, our preliminary study have discovered
and functionally characterized a group of ADME(drug absorption, distribution, metabolism, and excretion)
chemo-resistance lncRNAs, including LINC00992, whose up-regulation is associated with resistance to more
than 100 chemotherapy compounds and may regulate drug-metabolizing enzymes and transporters through
interacting with xenobiotic nuclear receptor. We hypothesize that dysregulation of ADME chemo-resistance
lncRNAs is an important contributor for the development of cancer chemo-resistance. Mechanistically, ADME
chemo-resistance lncRNAs affect chemo-resistance through their regulation of drug-metabolizing enzymes and
transporters that are responsible for the metabolism and disposition of chemotherapy drugs. We propose three
specific aims to test our hypotheses: In Aim 1, we will perform bioinformatic analysis and molecularly clone of
lncRNAs associated with cancer chemo-resistance and clinical prognosis. In Aim 2: we will functional
characterize of ADME chemo-resistance lncRNAs, including LINC00992, using in vivo and in vitro cancer
chemotherapy models. In Aim 3: we will determine the mechanism by which ADME chemo-resistance
lncRNAs, including LINC00992, regulate the expression of drug-metabolizing enzymes and transporters.
Chemotherapy remains a mainstay in the clinical management of cancer patients, but chemo-resistance is a
major challenge to overcome. Understanding the novel lncRNA responsive and xenobiotic nuclear receptor-
mediated chemo-resistance will help provide novel strategies to enhance therapeutic efficacy and avoid the
development of chemo-resistance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancer RNAs Boost MYC-Chromatin Interaction to Regulate Gene Expression and Tumorigenesis
-
批准号:10716358
-
项目类别:
-
资助金额:$43.4万
-
财政年份:2023
-
负责人:Da Yang
-
依托单位:
LncRNA EPIC1 induces immunotherapy resistance by activating EZH2 in breast cancer
-
批准号:10735281
-
项目类别:
-
资助金额:$40.62万
-
财政年份:2023
-
负责人:Da Yang
-
依托单位:
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition
-
批准号:10096096
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2020
-
负责人:Da Yang
-
依托单位:
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition
-
批准号:10307998
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2020
-
负责人:Da Yang
-
依托单位:
The oncogenic role of EPIC1MYC axis in breast cancer
-
批准号:9754801
-
项目类别:
-
资助金额:$34.73万
-
财政年份:2018
-
负责人:Da Yang
-
依托单位:
The oncogenic role of EPIC1MYC axis in breast cancer
-
批准号:10463712
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2018
-
负责人:Da Yang
-
依托单位:
The oncogenic role of EPIC1MYC axis in breast cancer
-
批准号:10214561
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2018
-
负责人:Da Yang
-
依托单位:
The oncogenic role of EPIC1MYC axis in breast cancer
-
批准号:9981699
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2018
-
负责人:Da Yang
-
依托单位:
海外基金